FMD alert issued for diamorphine hydrochloride lyophilisate for solution by MHRA
A defect in the 2D matrix for the expiration date of diamorphine hydrochloride lyophilisate for solution has been announced by the MHRA.
List view / Grid view
A defect in the 2D matrix for the expiration date of diamorphine hydrochloride lyophilisate for solution has been announced by the MHRA.
Side effects revealed during post-marketing experience are not listed on Atrolak XL prolonged-release tablet patient information leaflets, announces the MHRA.
Sanofi has won the latest appeal for the patent of its top oncology product, Jevtana (cabazitaxel).